首页 > 最新文献

European journal of preventive cardiology最新文献

英文 中文
"Split Impact: Road Traffic Directly Strains the Heart, Railway Noise Fuels Metabolic Risk-The Need for Tailored Noise Control". "双重影响:道路交通直接加重心脏负担,铁路噪声加剧代谢风险--需要有针对性的噪声控制"。
IF 8.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-04 DOI: 10.1093/eurjpc/zwae366
Thomas Münzel, Andreas Daiber
{"title":"\"Split Impact: Road Traffic Directly Strains the Heart, Railway Noise Fuels Metabolic Risk-The Need for Tailored Noise Control\".","authors":"Thomas Münzel, Andreas Daiber","doi":"10.1093/eurjpc/zwae366","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae366","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vitamin D status, physical activity and long-term mortality risk after myocardial infarction: a prospective analysis in the Alpha Omega Cohort. 维生素 D 状态、体力活动和心肌梗死后的长期死亡风险:阿尔法-欧米茄队列的前瞻性分析。
IF 8.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-04 DOI: 10.1093/eurjpc/zwae359
Esther Cruijsen, Claudia S van Pijkeren, Ilse Evers, Frank L J Visseren, Johanna M Geleijnse

Aim: In post-myocardial infarction (MI) patients, we examined independent and combined associations of vitamin D status and physical activity (PA) with long-term mortality, including effect modification by health determinants.

Methods: We conducted a prospective analysis of 4,837 MI patients from the Alpha Omega Cohort. Baseline blood samples (2002-2006) were assessed for plasma 25-hydroxyvitamin D (25[OH]D) levels using LC-MS/MS. PA was assessed using a validated questionnaire. Patients were followed for mortality through December 2022. HRs for CVD and all-cause mortality were obtained across sex-specific tertiles of 25(OH)D and four categories of PA using Cox models, adjusted for sociodemographic and lifestyle factors. Potential effect modification by health determinants was examined through stratification.

Results: Patients were 69±5.6 years old, 78% was male, 21% had diabetes, and 10% used vitamin D-containing supplements. Over 14.4 years, 3,206 deaths occurred, including 1,244 from CVD. Median 25(OH)D was 21.1 ng/mL and 44% was vitamin D deficient (<20 ng/mL). Higher 25(OH)D levels were associated with lower CVD (HR:0.63, 95%CI:0.54,0.74) and all-cause mortality (HR:0.68, 95%CI:0.62,0.75). For PA levels (high vs. light), HRs were 0.72 (95%CI:0.61,0.85) for CVD mortality and 0.83 (95%CI:0.75,0.92) for all-cause mortality. Patients with low 25(OH)D and no PA had a threefold higher mortality risk than those with high 25(OH)D levels and high PA. The associations were not significantly modified by sex, comorbidities and other health determinants.

Conclusions: Vitamin D status and PA were inversely and independently associated with long-term risk of CVD and all-cause mortality after MI, regardless of other health determinants.

目的:在心肌梗塞(MI)后患者中,我们研究了维生素 D 状态和体力活动(PA)与长期死亡率的独立和组合关系,包括健康决定因素的影响:我们对阿尔法-欧米茄队列中的 4837 名心肌梗死患者进行了前瞻性分析。采用 LC-MS/MS 对基线血样(2002-2006 年)的血浆 25- 羟维生素 D(25[OH]D)水平进行了评估。使用有效问卷对 PA 进行评估。对患者死亡率的跟踪调查一直持续到 2022 年 12 月。使用 Cox 模型得出了 25(OH)D 和四类 PA 的不同性别特异性 tertiles 的心血管疾病和全因死亡率 HRs,并对社会人口和生活方式因素进行了调整。通过分层对健康决定因素的潜在影响进行了研究:患者年龄为 69±5.6 岁,78% 为男性,21% 患有糖尿病,10% 使用含维生素 D 的补充剂。14.4年间,共有3206人死亡,其中1244人死于心血管疾病。25(OH)D 中位数为 21.1 纳克/毫升,44% 的人缺乏维生素 D(结论:维生素 D 状态与 PA 呈正相关):维生素 D 状态和 PA 与心肌梗死后心血管疾病和全因死亡率的长期风险呈独立的反向关系,与其他健康决定因素无关。
{"title":"Vitamin D status, physical activity and long-term mortality risk after myocardial infarction: a prospective analysis in the Alpha Omega Cohort.","authors":"Esther Cruijsen, Claudia S van Pijkeren, Ilse Evers, Frank L J Visseren, Johanna M Geleijnse","doi":"10.1093/eurjpc/zwae359","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae359","url":null,"abstract":"<p><strong>Aim: </strong>In post-myocardial infarction (MI) patients, we examined independent and combined associations of vitamin D status and physical activity (PA) with long-term mortality, including effect modification by health determinants.</p><p><strong>Methods: </strong>We conducted a prospective analysis of 4,837 MI patients from the Alpha Omega Cohort. Baseline blood samples (2002-2006) were assessed for plasma 25-hydroxyvitamin D (25[OH]D) levels using LC-MS/MS. PA was assessed using a validated questionnaire. Patients were followed for mortality through December 2022. HRs for CVD and all-cause mortality were obtained across sex-specific tertiles of 25(OH)D and four categories of PA using Cox models, adjusted for sociodemographic and lifestyle factors. Potential effect modification by health determinants was examined through stratification.</p><p><strong>Results: </strong>Patients were 69±5.6 years old, 78% was male, 21% had diabetes, and 10% used vitamin D-containing supplements. Over 14.4 years, 3,206 deaths occurred, including 1,244 from CVD. Median 25(OH)D was 21.1 ng/mL and 44% was vitamin D deficient (<20 ng/mL). Higher 25(OH)D levels were associated with lower CVD (HR:0.63, 95%CI:0.54,0.74) and all-cause mortality (HR:0.68, 95%CI:0.62,0.75). For PA levels (high vs. light), HRs were 0.72 (95%CI:0.61,0.85) for CVD mortality and 0.83 (95%CI:0.75,0.92) for all-cause mortality. Patients with low 25(OH)D and no PA had a threefold higher mortality risk than those with high 25(OH)D levels and high PA. The associations were not significantly modified by sex, comorbidities and other health determinants.</p><p><strong>Conclusions: </strong>Vitamin D status and PA were inversely and independently associated with long-term risk of CVD and all-cause mortality after MI, regardless of other health determinants.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Left Ventricular Volume as a Predictor of Exercise Capacity and Functional Independence in Individuals with Normal Ejection Fraction. 左心室容积是射血分数正常者运动能力和功能独立性的预测指标。
IF 8.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-04 DOI: 10.1093/eurjpc/zwae363
Stephanie Rowe, Wouter L'Hoyes, Mauricio Milani, Luke Spencer, Stephen Foulkes, Elizabeth Paratz, Kristel Janssens, Jan Stassen, Boris Delpire, Rik Pauwels, Sara Moura-Ferreira, Maarten Falter, Youri Bekhuis, Lieven Herbots, Mark J Haykowsky, Guido Claessen, Andre La Gerche, Jan Verwerft

Aims: Low cardiorespiratory fitness (CRF) is associated with functional disability, heart failure and mortality. Left ventricular (LV) end-diastolic volume (LVEDV) has been linked with CRF, but its utility as a diagnostic marker of low CRF has not been tested.

Methods: This multi-center international cohort examined the relationship between LV size on echocardiography and CRF (peak oxygen uptake [peak VO2] from cardiopulmonary exercise testing) in individuals with LV ejection fraction ≥50%. Absolute and BSA-indexed LVEDV (LVEDVi) were tested as predictors of low CRF and functional disability (peak VO2 <1100ml/min or <18 ml/kg/min) and compared against candidate measures of cardiac structure and function.

Results: 2876 individuals (309 endurance athletes, 251 healthy non-athletes, 1969 individuals with unexplained dyspnea, 347 individuals with heart failure with preserved ejection fraction) were included. For the entire cohort, LVEDV had the strongest univariable association with peak VO2 (R2 =0.45, standardized [std]β 0.67, p<0.001) and remained the strongest independent predictor of peak VO2 after adjusting for age, sex and BMI (stdβ 0.30, p<0.001). LVEDV was better at identifying low CRF than most established echocardiographic measures (LVEDV AUC 0.72; LVEDVi AUC 0.71), but equivalent to the E/e' ratio. The probability of achieving a peak VO2 below the functional independence threshold was highest for smaller ventricular volumes, with LVEDV and LVEDVi of 88ml and 57ml/m2 providing the optimal cut-points, respectively.

Conclusions: Small resting ventricular size is associated with a higher probability of low CRF and functional disability. LV size is the strongest independent echocardiographic predictor of CRF across the health-disease continuum.

目的:低心肺功能(CRF)与功能性残疾、心力衰竭和死亡率有关。左心室舒张末期容积(LVEDV)与心肺功能不全有关,但其作为低心肺功能诊断标志物的效用尚未得到检验:该多中心国际队列研究了左心室射血分数≥50%的患者超声心动图显示的左心室大小与CRF(心肺运动测试得出的摄氧量峰值[VO2峰值])之间的关系。结果:共纳入 2876 人(309 名耐力运动员、251 名健康非运动员、1969 名不明原因呼吸困难患者、347 名射血分数保留的心力衰竭患者)。在整个队列中,LVEDV 与峰值 VO2 的单变量关联性最强(R2 =0.45,标准化[std]β为 0.67,p结论:静息心室过小与低CRF和功能性残疾的概率较高有关。左心室大小是在健康与疾病之间预测 CRF 的最强独立超声心动图指标。
{"title":"Left Ventricular Volume as a Predictor of Exercise Capacity and Functional Independence in Individuals with Normal Ejection Fraction.","authors":"Stephanie Rowe, Wouter L'Hoyes, Mauricio Milani, Luke Spencer, Stephen Foulkes, Elizabeth Paratz, Kristel Janssens, Jan Stassen, Boris Delpire, Rik Pauwels, Sara Moura-Ferreira, Maarten Falter, Youri Bekhuis, Lieven Herbots, Mark J Haykowsky, Guido Claessen, Andre La Gerche, Jan Verwerft","doi":"10.1093/eurjpc/zwae363","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae363","url":null,"abstract":"<p><strong>Aims: </strong>Low cardiorespiratory fitness (CRF) is associated with functional disability, heart failure and mortality. Left ventricular (LV) end-diastolic volume (LVEDV) has been linked with CRF, but its utility as a diagnostic marker of low CRF has not been tested.</p><p><strong>Methods: </strong>This multi-center international cohort examined the relationship between LV size on echocardiography and CRF (peak oxygen uptake [peak VO2] from cardiopulmonary exercise testing) in individuals with LV ejection fraction ≥50%. Absolute and BSA-indexed LVEDV (LVEDVi) were tested as predictors of low CRF and functional disability (peak VO2 <1100ml/min or <18 ml/kg/min) and compared against candidate measures of cardiac structure and function.</p><p><strong>Results: </strong>2876 individuals (309 endurance athletes, 251 healthy non-athletes, 1969 individuals with unexplained dyspnea, 347 individuals with heart failure with preserved ejection fraction) were included. For the entire cohort, LVEDV had the strongest univariable association with peak VO2 (R2 =0.45, standardized [std]β 0.67, p<0.001) and remained the strongest independent predictor of peak VO2 after adjusting for age, sex and BMI (stdβ 0.30, p<0.001). LVEDV was better at identifying low CRF than most established echocardiographic measures (LVEDV AUC 0.72; LVEDVi AUC 0.71), but equivalent to the E/e' ratio. The probability of achieving a peak VO2 below the functional independence threshold was highest for smaller ventricular volumes, with LVEDV and LVEDVi of 88ml and 57ml/m2 providing the optimal cut-points, respectively.</p><p><strong>Conclusions: </strong>Small resting ventricular size is associated with a higher probability of low CRF and functional disability. LV size is the strongest independent echocardiographic predictor of CRF across the health-disease continuum.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arrhythmic risk stratification in patients with left ventricular ring-like scar. 左心室环状瘢痕患者的心律失常风险分层。
IF 8.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1093/eurjpc/zwae353
Vanda Parisi, Maddalena Graziosi, Luis R Lopes, Antonio De Luca, Ferdinando Pasquale, Giacomo Tini, Mattia Targetti, Maria R Cueto, Ana R Moura, Raffaello Ditaranto, Camilla Torlasco, Nevio Taglieri, Elena Nardi, Luigi Lovato, João B Augusto, Nazzareno Galiè, Lia Crotti, Alessio Gasperetti, Mauro Biffi, Camillo Autore, Marco Merlo, Iacopo Olivotto, Gianfranco Sinagra, Perry M Elliott, Elena Biagini

Aims: Left ventricular (LV) ring-like scar on cardiac magnetic resonance (CMR) has been linked to malignant arrhythmias in patients with non-ischemic cardiomyopathy. This study aimed to perform a comprehensive evaluation of this phenotype and to identify risk factors for life-threatening arrhythmic events (LAEs), a composite of sudden cardiac death (SCD), aborted SCD, and sustained ventricular tachycardia.

Methods and results: One-hundred-fifteen patients (median age 39 [IQR 28-52], 42% females) were identified at 6 referral centres. Inclusion criteria were ring-like LV scar (≥ 3 contiguous segments with subepicardial/midwall late gadolinium enhancement (LGE) in the same slice) and one among: pathogenic/likely pathogenic genetic variant, family history for cardiomyopathy, or arrhythmogenic cardiomyopathy diagnosis. During the study follow-up, survival-free from LAEs was 60% (3.8 events/100 patients/year); at a median follow-up of 4.6 years (IQR 1.7-8.4) it was 84%. On multivariable analysis, anterior Q waves (HR:1.030, 95% CI:1.014-1.046, p < 0.001), QRS width (HR:4.642, 95% CI:1.296-16.628, p=0.018), and LV end-diastolic volume index (LVEDVi) (HR:1.011, 95% CI:1.001-1.021, per mL/m2 increase, p=0.040) were independently associated with LAEs; with good discrimination power (Harrell's C-index=0.796). Three risk categories were identified: normal ECG, abnormal ECG and no LAEs predictive variables, abnormal ECG and ≥ 1 LAEs predictive variables, with a decreasing survival from 100% to 65% and 49%, respectively (Log-rank test = 0.015).

Conclusions: In this study, the LV ring-like scar phenotype was associated with a high rate of malignant arrhythmias in presence of anterior Q waves, QRS prolongation, and increased LVEDVi. A normal ECG identified a lower risk subgroup.

目的:心脏磁共振(CMR)显示的左心室环状瘢痕与非缺血性心肌病患者的恶性心律失常有关。本研究旨在对这一表型进行全面评估,并确定危及生命的心律失常事件(LAEs)的风险因素,即心脏性猝死(SCD)、SCD流产和持续性室性心动过速的综合因素:在 6 个转诊中心确定了 115 名患者(中位年龄 39 [IQR:28-52],42% 为女性)。纳入标准为环状左心室瘢痕(同一切片中心外膜下/中壁晚期钆增强(LGE)的连续节段≥3个)以及致病/可能致病基因变异、心肌病家族史或心律失常性心肌病诊断中的一项。研究随访期间,LAEs的无存活率为60%(3.8例/100名患者/年);中位随访4.6年(IQR 1.7-8.4),无存活率为84%。在多变量分析中,前方 Q 波(HR:1.030,95% CI:1.014-1.046,p <0.001)、QRS 宽度(HR:4.642,95% CI:1.296-16.628,p=0.018)和 LV 舒张末期容积指数(LVEDVi)(HR:1.011,95% CI:1.001-1.021,每 mL/m2 增加,p=0.040)与 LAEs 独立相关;具有良好的鉴别力(Harrell's C-index=0.796)。确定了三个风险类别:正常心电图、异常心电图和无LAEs预测变量、异常心电图和≥1个LAEs预测变量,存活率分别从100%降至65%和49%(Log-rank检验=0.015):在这项研究中,左心室环状瘢痕表型与前Q波、QRS延长和LVEDVi增高相关的恶性心律失常发生率较高。心电图正常的亚组风险较低。
{"title":"Arrhythmic risk stratification in patients with left ventricular ring-like scar.","authors":"Vanda Parisi, Maddalena Graziosi, Luis R Lopes, Antonio De Luca, Ferdinando Pasquale, Giacomo Tini, Mattia Targetti, Maria R Cueto, Ana R Moura, Raffaello Ditaranto, Camilla Torlasco, Nevio Taglieri, Elena Nardi, Luigi Lovato, João B Augusto, Nazzareno Galiè, Lia Crotti, Alessio Gasperetti, Mauro Biffi, Camillo Autore, Marco Merlo, Iacopo Olivotto, Gianfranco Sinagra, Perry M Elliott, Elena Biagini","doi":"10.1093/eurjpc/zwae353","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae353","url":null,"abstract":"<p><strong>Aims: </strong>Left ventricular (LV) ring-like scar on cardiac magnetic resonance (CMR) has been linked to malignant arrhythmias in patients with non-ischemic cardiomyopathy. This study aimed to perform a comprehensive evaluation of this phenotype and to identify risk factors for life-threatening arrhythmic events (LAEs), a composite of sudden cardiac death (SCD), aborted SCD, and sustained ventricular tachycardia.</p><p><strong>Methods and results: </strong>One-hundred-fifteen patients (median age 39 [IQR 28-52], 42% females) were identified at 6 referral centres. Inclusion criteria were ring-like LV scar (≥ 3 contiguous segments with subepicardial/midwall late gadolinium enhancement (LGE) in the same slice) and one among: pathogenic/likely pathogenic genetic variant, family history for cardiomyopathy, or arrhythmogenic cardiomyopathy diagnosis. During the study follow-up, survival-free from LAEs was 60% (3.8 events/100 patients/year); at a median follow-up of 4.6 years (IQR 1.7-8.4) it was 84%. On multivariable analysis, anterior Q waves (HR:1.030, 95% CI:1.014-1.046, p < 0.001), QRS width (HR:4.642, 95% CI:1.296-16.628, p=0.018), and LV end-diastolic volume index (LVEDVi) (HR:1.011, 95% CI:1.001-1.021, per mL/m2 increase, p=0.040) were independently associated with LAEs; with good discrimination power (Harrell's C-index=0.796). Three risk categories were identified: normal ECG, abnormal ECG and no LAEs predictive variables, abnormal ECG and ≥ 1 LAEs predictive variables, with a decreasing survival from 100% to 65% and 49%, respectively (Log-rank test = 0.015).</p><p><strong>Conclusions: </strong>In this study, the LV ring-like scar phenotype was associated with a high rate of malignant arrhythmias in presence of anterior Q waves, QRS prolongation, and increased LVEDVi. A normal ECG identified a lower risk subgroup.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142562636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
External validation of SCORE2-Diabetes in the Netherlands across various Socioeconomic levels in native-Dutch and non-Dutch populations. SCORE2-Diabetes 在荷兰不同社会经济水平的本土荷兰人和非荷兰人中的外部验证。
IF 8.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1093/eurjpc/zwae354
Sukainah A Alfaraj, Janet M Kist, Rolf H H Groenwold, Marco Spruit, Dennis Mook-Kanamori, Rimke C Vos

Aims: Adults with type 2 diabetes have an increased risk of cardiovascular events (CVE), the world's leading cause of mortality. The SCORE2-Diabetes model is a tool designed to estimate the 10-year risk of CVE specifically in individuals with type 2 diabetes. However, the performance of such models may vary across different demographic and socioeconomic groups, necessitating validation and assessment in diverse populations. This study aims to externally validate SCORE2-Diabetes and assess its performance across various socioeconomic and migration origins in the Netherlands.

Methods: We selected adults with type 2 diabetes, aged 40-79 years and without previous CVE from the Extramural LUMC Academic Network (ELAN) primary care data cohort from 2007 to 2023. ELAN data were linked with Statistics Netherlands registry data to obtain information about the country of origin and socioeconomic status (SES). CVE was defined as myocardial infarction, stroke, or CV mortality. Non-CV mortality was considered a competing event. Analyses were stratified by sex, Dutch versus other non-Dutch countries of origin, and quintiles of SES.

Results: Of the 26,544 included adults with type 2 diabetes, 2,518 developed CVE. SCORE2-Diabetes showed strong predictive accuracy for CVE in the Dutch population (observed-to-expected ratio (OE)=1.000, 95% CI=0.990-1.008 for men, and OE=1.050, 95% CI=1.042-1.057 for women). For non-Dutch individuals, the model underestimated CVE risk (OE=1.121, 95% CI=1.108-1.131 for men, and OE=1.100, 95% CI=1.092-1.111 for women). The model also underestimated the CVE risk (OE>1) in low SES groups and overestimated the risk (OE<1) in high SES groups. Discrimination was moderate across subgroups with c-indices between 0.6 and 0.7.

Conclusions: SCORE2-Diabetes accurately predicted the risk of CVE in the Dutch population. However, it underpredicted the risk of CVE in the low SES groups and non-Dutch origins, while overpredicting the risk in high SES men and women. Additional clinical judgment must be considered when using SCORE2-Diabetes for different SES and countries of origin.

目的:成人 2 型糖尿病患者发生心血管事件 (CVE) 的风险增加,而心血管事件是世界上导致死亡的主要原因。SCORE2-Diabetes 模型是一种专门用于估算 2 型糖尿病患者 10 年 CVE 风险的工具。然而,在不同的人口和社会经济群体中,此类模型的性能可能会有所不同,因此有必要在不同的人群中进行验证和评估。本研究旨在对 SCORE2-Diabetes 进行外部验证,并评估其在荷兰不同社会经济和移民来源人群中的表现:我们从校外 LUMC 学术网络(ELAN)2007 年至 2023 年的初级保健数据队列中选取了年龄在 40-79 岁之间、既往无 CVE 的 2 型糖尿病成人患者。ELAN数据与荷兰统计局的登记数据相链接,以获得有关原籍国和社会经济地位(SES)的信息。CVE定义为心肌梗死、中风或CV死亡率。非 CV 死亡率被视为竞争事件。按照性别、荷兰原籍国与其他非荷兰原籍国以及社会经济地位五分位数进行了分层分析:结果:在纳入的 26,544 名 2 型糖尿病成人患者中,有 2,518 人罹患 CVE。在荷兰人群中,SCORE2-Diabetes 对 CVE 的预测准确性很高(男性的观察值与预期值之比 (OE)=1.000, 95% CI=0.990-1.008; 女性的观察值与预期值之比 (OE)=1.050, 95% CI=1.042-1.057 )。对于非荷兰人,该模型低估了CVE风险(男性OE=1.121,95% CI=1.108-1.131;女性OE=1.100,95% CI=1.092-1.111)。该模型还低估了低社会经济地位群体的 CVE 风险(OE>1),并高估了风险(OEC结论:SCORE2-Diabetes 可准确预测荷兰人口的 CVE 风险。然而,它低估了低社会经济地位群体和非荷兰裔人群的 CVE 风险,而高估了高社会经济地位男性和女性的 CVE 风险。在针对不同的社会经济地位和原籍国使用 SCORE2-Diabetes 时,必须考虑额外的临床判断。
{"title":"External validation of SCORE2-Diabetes in the Netherlands across various Socioeconomic levels in native-Dutch and non-Dutch populations.","authors":"Sukainah A Alfaraj, Janet M Kist, Rolf H H Groenwold, Marco Spruit, Dennis Mook-Kanamori, Rimke C Vos","doi":"10.1093/eurjpc/zwae354","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae354","url":null,"abstract":"<p><strong>Aims: </strong>Adults with type 2 diabetes have an increased risk of cardiovascular events (CVE), the world's leading cause of mortality. The SCORE2-Diabetes model is a tool designed to estimate the 10-year risk of CVE specifically in individuals with type 2 diabetes. However, the performance of such models may vary across different demographic and socioeconomic groups, necessitating validation and assessment in diverse populations. This study aims to externally validate SCORE2-Diabetes and assess its performance across various socioeconomic and migration origins in the Netherlands.</p><p><strong>Methods: </strong>We selected adults with type 2 diabetes, aged 40-79 years and without previous CVE from the Extramural LUMC Academic Network (ELAN) primary care data cohort from 2007 to 2023. ELAN data were linked with Statistics Netherlands registry data to obtain information about the country of origin and socioeconomic status (SES). CVE was defined as myocardial infarction, stroke, or CV mortality. Non-CV mortality was considered a competing event. Analyses were stratified by sex, Dutch versus other non-Dutch countries of origin, and quintiles of SES.</p><p><strong>Results: </strong>Of the 26,544 included adults with type 2 diabetes, 2,518 developed CVE. SCORE2-Diabetes showed strong predictive accuracy for CVE in the Dutch population (observed-to-expected ratio (OE)=1.000, 95% CI=0.990-1.008 for men, and OE=1.050, 95% CI=1.042-1.057 for women). For non-Dutch individuals, the model underestimated CVE risk (OE=1.121, 95% CI=1.108-1.131 for men, and OE=1.100, 95% CI=1.092-1.111 for women). The model also underestimated the CVE risk (OE>1) in low SES groups and overestimated the risk (OE<1) in high SES groups. Discrimination was moderate across subgroups with c-indices between 0.6 and 0.7.</p><p><strong>Conclusions: </strong>SCORE2-Diabetes accurately predicted the risk of CVE in the Dutch population. However, it underpredicted the risk of CVE in the low SES groups and non-Dutch origins, while overpredicting the risk in high SES men and women. Additional clinical judgment must be considered when using SCORE2-Diabetes for different SES and countries of origin.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142562668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Beyond the Walk: The Prognostic value of Dyspnea in Heart Failure". "超越行走:心力衰竭患者呼吸困难的预后价值"。
IF 8.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1093/eurjpc/zwae358
Geza Halasz, Raffaella Mistrulli
{"title":"\"Beyond the Walk: The Prognostic value of Dyspnea in Heart Failure\".","authors":"Geza Halasz, Raffaella Mistrulli","doi":"10.1093/eurjpc/zwae358","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae358","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effects of Colchicine on Lipoprotein(a) and Oxidized Phospholipid Associated Cardiovascular Disease Risk. 秋水仙碱对脂蛋白(a)和氧化磷脂相关心血管疾病风险的影响
IF 8.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-30 DOI: 10.1093/eurjpc/zwae355
Niekbachsh Mohammadnia, Amber van Broekhoven, Willem A Bax, John W Eikelboom, Arend Mosterd, Aernoud T L Fiolet, Jan G P Tijssen, Peter L Thompson, Dominique P V de Kleijn, Sotirios Tsimikas, Jan H Cornel, Calvin Yeang, Saloua El Messaoudi

Aims: Inflammatory lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs) on lipoproteins convey residual cardiovascular disease risk. The LoDoCo2 (low-dose colchicine 2) trial showed that colchicine reduced the risk for cardiovascular events occurring on standard therapies in patients with chronic coronary disease (CCS). We explored the effects of colchicine on Lp(a) and oxidized lipoprotein associated risk in a LoDoCo2 biomarker subpopulation.

Methods: Lp(a), OxPLs on apolipoprotein(a) [OxPL-apo(a)] and apolipoprotein B (OxPL-apoB) levels were determined in the biomarker population of the LoDoCo2 trial (n = 1777). Cox regression analysis was used to compare the risk for the primary endpoint, consisting of myocardial infarction, ischemic stroke, or ischemia-driven revascularization by biomarker levels. Interactions between treatment, Lp(a) and OxPL levels were evaluated.

Results: Lp(a), OxPL-apo(a) and OxPL-apoB levels were similar between the colchicine and placebo groups. Consistent risk reduction by colchicine was observed in those with Lp(a) <125 nmol/L and ≥125 nmol/L, and the highest OxPL-apo(a) tertile compared to the lowest (Pinteraction=0.92 and 0.66). The absolute risk reduction for those with Lp(a) ≥125 nmol/L appeared higher compared to those with Lp(a) <125 nmol/L (4.4% vs 2.4%). A treatment interaction for colchicine was found in those with the highest OxPL-apoB tertile vs the lowest (Pinteraction=0.04).

Conclusion: In patients with CCS, colchicine reduces cardiovascular disease risk in those with and without elevated Lp(a) but absolute benefits appeared higher in those with Lp(a) ≥125 nmol/L. Patients with higher levels of OxPL-apoB experienced greater benefit of colchicine, suggesting colchicine may be more effective in subjects with heightened oxidation-driven inflammation.

目的:脂蛋白上的炎性脂蛋白(a)[Lp(a)]和氧化磷脂(OxPLs)传递着残留的心血管疾病风险。LoDoCo2(低剂量秋水仙碱 2)试验表明,秋水仙碱可降低慢性冠心病(CCS)患者接受标准疗法后发生心血管事件的风险。我们探讨了秋水仙碱对 LoDoCo2 生物标志物亚群中脂蛋白(a)和氧化脂蛋白相关风险的影响:在 LoDoCo2 试验的生物标志物人群(n = 1777)中测定脂蛋白(a)、脂蛋白(a)上的氧化脂蛋白[OxPL-apo(a)]和脂蛋白 B(OxPL-apoB)水平。采用 Cox 回归分析比较了生物标志物水平对主要终点(包括心肌梗死、缺血性中风或缺血性血运重建)的风险影响。评估了治疗、脂蛋白(a)和OxPL水平之间的相互作用:结果:秋水仙碱组和安慰剂组的脂蛋白(a)、OxPL-apo(a)和 OxPL-apoB 水平相似。结果:秋水仙碱组和安慰剂组的 Lp(a)和 OxPL-apo(a) 和 OxPL-apoB 水平相似:在 CCS 患者中,无论 Lp(a)是否升高,秋水仙碱都能降低心血管疾病风险,但 Lp(a)≥125 nmol/L 患者的绝对获益更高。OxPL-apoB水平较高的患者从秋水仙碱中获益更大,这表明秋水仙碱对氧化驱动炎症加剧的受试者可能更有效。
{"title":"The Effects of Colchicine on Lipoprotein(a) and Oxidized Phospholipid Associated Cardiovascular Disease Risk.","authors":"Niekbachsh Mohammadnia, Amber van Broekhoven, Willem A Bax, John W Eikelboom, Arend Mosterd, Aernoud T L Fiolet, Jan G P Tijssen, Peter L Thompson, Dominique P V de Kleijn, Sotirios Tsimikas, Jan H Cornel, Calvin Yeang, Saloua El Messaoudi","doi":"10.1093/eurjpc/zwae355","DOIUrl":"10.1093/eurjpc/zwae355","url":null,"abstract":"<p><strong>Aims: </strong>Inflammatory lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs) on lipoproteins convey residual cardiovascular disease risk. The LoDoCo2 (low-dose colchicine 2) trial showed that colchicine reduced the risk for cardiovascular events occurring on standard therapies in patients with chronic coronary disease (CCS). We explored the effects of colchicine on Lp(a) and oxidized lipoprotein associated risk in a LoDoCo2 biomarker subpopulation.</p><p><strong>Methods: </strong>Lp(a), OxPLs on apolipoprotein(a) [OxPL-apo(a)] and apolipoprotein B (OxPL-apoB) levels were determined in the biomarker population of the LoDoCo2 trial (n = 1777). Cox regression analysis was used to compare the risk for the primary endpoint, consisting of myocardial infarction, ischemic stroke, or ischemia-driven revascularization by biomarker levels. Interactions between treatment, Lp(a) and OxPL levels were evaluated.</p><p><strong>Results: </strong>Lp(a), OxPL-apo(a) and OxPL-apoB levels were similar between the colchicine and placebo groups. Consistent risk reduction by colchicine was observed in those with Lp(a) <125 nmol/L and ≥125 nmol/L, and the highest OxPL-apo(a) tertile compared to the lowest (Pinteraction=0.92 and 0.66). The absolute risk reduction for those with Lp(a) ≥125 nmol/L appeared higher compared to those with Lp(a) <125 nmol/L (4.4% vs 2.4%). A treatment interaction for colchicine was found in those with the highest OxPL-apoB tertile vs the lowest (Pinteraction=0.04).</p><p><strong>Conclusion: </strong>In patients with CCS, colchicine reduces cardiovascular disease risk in those with and without elevated Lp(a) but absolute benefits appeared higher in those with Lp(a) ≥125 nmol/L. Patients with higher levels of OxPL-apoB experienced greater benefit of colchicine, suggesting colchicine may be more effective in subjects with heightened oxidation-driven inflammation.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking Cholesterol: The Role of Lipophilic Pollutants. 重新思考胆固醇:亲脂污染物的作用。
IF 8.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-30 DOI: 10.1093/eurjpc/zwae350
Duk-Hee Lee, David R Jacobs, P Monica Lind, Lars Lind
{"title":"Rethinking Cholesterol: The Role of Lipophilic Pollutants.","authors":"Duk-Hee Lee, David R Jacobs, P Monica Lind, Lars Lind","doi":"10.1093/eurjpc/zwae350","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae350","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adding traditional and emerging biomarkers for risk assessment in secondary prevention: A prospective cohort study of 20,656 patients with cardiovascular disease. 在二级预防风险评估中加入传统和新兴生物标记物:一项针对 20656 名心血管疾病患者的前瞻性队列研究。
IF 8.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-30 DOI: 10.1093/eurjpc/zwae352
Ike Dhiah Rochmawati, Salil Deo, Jennifer S Lees, Patrick B Mark, Naveed Sattar, Carlos Celis-Morales, Jill P Pell, Paul Welsh, Frederick K Ho

Background: This study aims to explore whether conventional and emerging biomarkers could improve risk discrimination and calibration in secondary prevention of recurrent atherosclerotic cardiovascular disease (ASCVD), based on a model using predictors from SMART2.

Methods: In a cohort of 20,658 UK Biobank participants with medical history of ASCVD, we analysed any improvement in C indices and net reclassification index (NRI) for future ASCVD events, following addition of LP-a, ApoB, cystatin C, HbA1c, GGT, AST, ALT, and ALP, to a model with predictors used in SMART2 for the outcome of recurrent major cardiovascular event. We also examined any improvement in C indices and NRIs replacing creatinine based estimated glomerular filtration rate (eGFR) with cystatin C based estimates. Calibration plots between different models were also compared.

Results: Compared with the baseline model (C index=0.663), modest increment in C indices were observed when adding HbA1c (ΔC=0.0064, p<0.001), cystatin C (ΔC=0.0037, p<0.001), GGT (ΔC=0.0023, p<0.001), AST (ΔC= 0.0007, p<0.005) or ALP (ΔC=0.0010, p<0.001) or replacing eGFRCr with eGFRCysC (ΔC=0.0036, p<0.001) or eGFRCr-CysC (ΔC=0.00336, p<0.001). Similarly, the strongest improvements in NRI were observed with the addition of HbA1c (NRI=0.014), or cystatin C (NRI= 0.006) or replacing eGFRCr with eGFRCr-CysC (NRI=0.001) or eGFRCysC (NRI=0.002). There was no evidence that adding biomarkers modify calibration.

Conclusions: Adding several biomarkers, most notably cystatin C and HbA1c, but not LP-a, in a model using SMART2 predictors modestly improved discrimination.

背景:本研究旨在探讨传统和新兴生物标志物是否能改善复发性动脉粥样硬化性心血管疾病(ASCVD)二级预防中的风险识别和校准,该模型基于 SMART2 的预测因子:在英国生物库 20658 名有 ASCVD 病史的参与者队列中,我们分析了将 LP-a、载脂蛋白 B、胱抑素 C、HbA1c、谷丙转氨酶、谷草转氨酶、谷草转氨酶和谷丙转氨酶添加到 SMART2 中使用的预测复发性主要心血管事件结果的模型中后,未来 ASCVD 事件的 C 指数和净重分类指数 (NRI) 是否有所改善。我们还研究了用基于胱抑素 C 的估计值取代基于肌酐的肾小球滤过率(eGFR)后,C 指数和 NRI 是否有所改善。我们还比较了不同模型之间的校准图:结果:与基线模型(C 指数=0.663)相比,加入 HbA1c 后,C 指数略有增加(ΔC=0.0064,pConclusions):在使用 SMART2 预测因子的模型中添加几种生物标志物,尤其是胱抑素 C 和 HbA1c,而不是 LP-a,可适度提高辨别能力。
{"title":"Adding traditional and emerging biomarkers for risk assessment in secondary prevention: A prospective cohort study of 20,656 patients with cardiovascular disease.","authors":"Ike Dhiah Rochmawati, Salil Deo, Jennifer S Lees, Patrick B Mark, Naveed Sattar, Carlos Celis-Morales, Jill P Pell, Paul Welsh, Frederick K Ho","doi":"10.1093/eurjpc/zwae352","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae352","url":null,"abstract":"<p><strong>Background: </strong>This study aims to explore whether conventional and emerging biomarkers could improve risk discrimination and calibration in secondary prevention of recurrent atherosclerotic cardiovascular disease (ASCVD), based on a model using predictors from SMART2.</p><p><strong>Methods: </strong>In a cohort of 20,658 UK Biobank participants with medical history of ASCVD, we analysed any improvement in C indices and net reclassification index (NRI) for future ASCVD events, following addition of LP-a, ApoB, cystatin C, HbA1c, GGT, AST, ALT, and ALP, to a model with predictors used in SMART2 for the outcome of recurrent major cardiovascular event. We also examined any improvement in C indices and NRIs replacing creatinine based estimated glomerular filtration rate (eGFR) with cystatin C based estimates. Calibration plots between different models were also compared.</p><p><strong>Results: </strong>Compared with the baseline model (C index=0.663), modest increment in C indices were observed when adding HbA1c (ΔC=0.0064, p<0.001), cystatin C (ΔC=0.0037, p<0.001), GGT (ΔC=0.0023, p<0.001), AST (ΔC= 0.0007, p<0.005) or ALP (ΔC=0.0010, p<0.001) or replacing eGFRCr with eGFRCysC (ΔC=0.0036, p<0.001) or eGFRCr-CysC (ΔC=0.00336, p<0.001). Similarly, the strongest improvements in NRI were observed with the addition of HbA1c (NRI=0.014), or cystatin C (NRI= 0.006) or replacing eGFRCr with eGFRCr-CysC (NRI=0.001) or eGFRCysC (NRI=0.002). There was no evidence that adding biomarkers modify calibration.</p><p><strong>Conclusions: </strong>Adding several biomarkers, most notably cystatin C and HbA1c, but not LP-a, in a model using SMART2 predictors modestly improved discrimination.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of cumulative LDL-C and other risk factors on CAD prevalence in patients with familial hypercholesterolemia. 家族性高胆固醇血症患者的累积 LDL-C 和其他风险因素对 CAD 患病率的影响。
IF 8.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-30 DOI: 10.1093/eurjpc/zwae349
Shirin Ibrahim, G Kees Hovingh, Barbara A Hutten, Erik S G Stroes, Laurens F Reeskamp
{"title":"Impact of cumulative LDL-C and other risk factors on CAD prevalence in patients with familial hypercholesterolemia.","authors":"Shirin Ibrahim, G Kees Hovingh, Barbara A Hutten, Erik S G Stroes, Laurens F Reeskamp","doi":"10.1093/eurjpc/zwae349","DOIUrl":"https://doi.org/10.1093/eurjpc/zwae349","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European journal of preventive cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1